Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Internal Medicine

RSS  

Articles

  • Does Amantadine Treatment Reduce Levodopa-Induced Dyskinesias?

    This retrospective cohort study compared the effect of amantadine on levodopa-induced dyskinesia (LID) onset with use of anticholinergics and monoamine oxidase type B inhibitors in patients with Parkinson’s disease. The authors concluded that early treatment with amantadine may delay LID onset more than treatment with other symptomatic agents.

  • Cognitive Outcomes After Mild Traumatic Brain Injury

    Mild traumatic brain injuries (mTBIs) may lead to adverse cognitive and neuropsychiatric outcomes. The pathways that lead to adverse cognitive outcomes remain to be scientifically elucidated. A prospective cohort study of 656 participants enrolled in the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study found that at one year, 13.5% of participants with mTBI had poor cognitive outcome compared to 4.5% of controls, highlighting the need for better understanding of the mechanisms leading to poor cognitive and functional outcomes after mTBIs and interventions to optimize cognitive recovery.

  • Identifying Community-Acquired Pneumonia During the COVID-19 Pandemic

    Pneumonia is an infection of the alveoli of the lungs. Alveolar infection results in inflammation that disrupts normal pulmonary function, producing impaired gas exchange. Pneumonia can be caused by bacteria, viruses, or fungi. Pathogens can infect the lung parenchyma through three routes: inhalation, aspiration, or hematogenous spread. In community-acquired pneumonia, the infection is initiated outside the hospital. The prevalence of COVID-19, the clinical disease caused by the SARS-CoV-2 virus, has changed the landscape of pneumonia.

  • Infectious Disease Alert Updates

    Recovering from Critical COVID; Oral and Anal Transmission of Syphilis

  • A Case of Monkeypox in a Returned Traveler

    The arrival of a traveler from Nigeria to the United States with monkeypox infection, which was quickly recognized, led to a massive public health response investigating exposed individuals, but no secondary cases were detected.


  • Maribavir (Livtencity)

    The FDA approved maribavir as the first drug to treat adult and pediatric patients with post-transplant cytomegalovirus infections that do not respond to currently available antiviral treatment.

  • Persistent Inflammation and Post-COVID Syndrome

    Ongoing inflammation may contribute to long COVID.

  • Immunosuppressants and the Risk for Clostridioides difficile Infection

    A retrospective cohort study found that for patients taking immunosuppressing medications, the greatest risk for C. difficile infection occurred for those receiving calcineurin inhibitors and those taking drugs from multiple immunosuppressant classes.

  • Aminoglycoside-Induced Ototoxicity: Test Before You Treat?

    Mitochondrially inherited, aminoglycoside-induced ototoxicity can cause irreversible hearing loss. Approximately 0.2% of the population is at risk, and new point-of-care genetic testing could prompt avoidance of aminoglycoside use without undue delay in antibiotic administration.

  • Midlines vs. Peripherally Inserted Central Venous Catheters

    Midline catheters are, at a minimum, at least as safe or safer than peripherally inserted central catheters for durations of at least 14 days, thus offering an effective alternative for venous access.